We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.
- Authors
Iorember, Franca; Nayak, Anjali
- Abstract
Deficiency of Complement Factor H Related (CFHR) plasma proteins and Autoantibody Positive Hemolytic Uremic Syndrome (DEAP-HUS) is a subtype of atypical hemolytic uremic syndrome, known to be associated with significant morbidity. Its pathogenesis is linked to the production of IgG autoantibodies against complement factor H, a regulator of the alternative complement pathway. The binding of the autoantibodies to the C terminal of complement factor H interferes with its regulatory function, leading to increased activation of the alternative complement pathway and consequent endothelial cellular damage. Early diagnosis and initiation of appropriate therapy is reported to lead to favorable outcomes. Institution of plasma exchange therapy within 24 h of diagnosis has been shown to rapidly lower antibody levels, leading to clinical improvement. Adjunctive immunosuppression therapy suppresses antibody production and helps in maintaining long-term clinical remission of the disease. Available data advocates a treatment regimen that combines plasma therapy (preferably plasma exchange) and immunosuppression to halt disease process and sustain long-term disease remission.
- Subjects
HEMOLYTIC-uremic syndrome treatment; HEMOLYTIC-uremic syndrome diagnosis; AUTOANTIBODIES; ENDOTHELIAL cells; COMPLEMENT (Immunology); BLOOD proteins; PLASMA exchange (Therapeutics); IMMUNOSUPPRESSION; PROTEIN deficiency; TREATMENT effectiveness; PATIENT monitoring; HEMOLYTIC-uremic syndrome; COMBINED modality therapy; EARLY diagnosis; DISEASE remission
- Publication
Pediatric Nephrology, 2021, Vol 36, Issue 6, p1365
- ISSN
0931-041X
- Publication type
Article
- DOI
10.1007/s00467-020-04652-x